SPBPB2B2.19c Antibody

What is the SPBPB2B2.19c Antibody and what organism does it target?

The SPBPB2B2.19c Antibody is a rabbit polyclonal antibody that recognizes proteins encoded by the SPBPB2B2.19c gene in Schizosaccharomyces pombe (strain 972). It also cross-reacts with the protein encoded by SPBC1348.02, suggesting sequence homology or structural similarity between these gene products . The antibody is raised against a recombinant immunogen derived from S. pombe, which is a well-established model organism in molecular and cell biology research. Methodologically, researchers should consider that as a polyclonal preparation, this antibody contains a heterogeneous mixture of immunoglobulins that recognize multiple epitopes on the target protein, potentially increasing detection sensitivity but also the possibility of cross-reactivity.

What are the recommended applications for SPBPB2B2.19c Antibody?

The SPBPB2B2.19c Antibody has been validated for enzyme-linked immunosorbent assay (ELISA) and Western blotting (WB) applications . For Western blotting, researchers should optimize protocols using the provided positive control (recombinant immunogen protein/peptide) to establish appropriate antibody dilutions, blocking conditions, and detection methods. For ELISA applications, the antibody can be used in both direct and indirect formats, with optimization of coating conditions, blocking buffers, and detection systems. When comparing results between these techniques, researchers should be aware that epitope accessibility may differ between native (ELISA) and denatured (Western blot) conformations of the target protein.

What components are provided with the SPBPB2B2.19c Antibody and how should they be utilized?

The antibody package includes three critical components that serve distinct research purposes:

Researchers should use the positive control when establishing assay conditions and determining antibody specificity. The pre-immune serum serves as an important negative control to distinguish between specific and non-specific signals, particularly in complex samples. Using both controls in parallel with experimental samples is critical for accurate data interpretation and validation of results .

How might cross-reactivity with homologous proteins affect experimental outcomes when using SPBPB2B2.19c Antibody?

The SPBPB2B2.19c Antibody recognizes proteins encoded by both SPBPB2B2.19c and SPBC1348.02 genes , which raises important considerations for experimental design and data interpretation. This cross-reactivity likely stems from sequence homology or structural similarity between these proteins. To differentiate between signals from these homologous proteins, researchers should implement several methodological approaches:

• Employ genetic models with single or double knockouts of these genes to establish signal specificity

• Perform immunoprecipitation followed by mass spectrometry to identify bound proteins

• Use competitive binding assays with recombinant proteins to quantify relative affinities

• Implement subcellular fractionation if the proteins localize to different cellular compartments

Similar to how researchers addressed cross-reactivity issues with antibodies targeting SARS-CoV-2 S2 protein that exhibited reactivity with gut bacterial proteins , investigators should conduct comprehensive epitope mapping and cross-adsorption studies to delineate the specificity profile of this antibody.

What strategies would optimize the SPBPB2B2.19c Antibody for immunoprecipitation studies investigating protein-protein interactions?

While the antibody is primarily validated for ELISA and Western blotting , researchers interested in adapting it for immunoprecipitation (IP) studies should consider the following optimization strategies:

• Antibody coupling approach: Covalently couple the antibody to a solid support (e.g., agarose or magnetic beads) using chemical crosslinkers to prevent heavy chain contamination in downstream analyses.

• Lysis buffer optimization: Test multiple lysis conditions to preserve protein-protein interactions while ensuring efficient extraction:

  • Low stringency: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, protease inhibitors

  • Medium stringency: Add 0.5% sodium deoxycholate

  • High stringency: Add 0.1% SDS

• Validation controls: Include IP with pre-immune serum and IP from cell lines lacking the target gene to establish specificity parameters.

• Crosslinking considerations: For transient interactions, implement in vivo crosslinking with formaldehyde (1%) or DSP (dithiobis[succinimidyl propionate]) prior to cell lysis.

This approach mirrors strategies used in developing bispecific antibodies for complex target systems, where maintaining conformational integrity is crucial for functional studies .

How might epitope accessibility in different experimental conditions affect SPBPB2B2.19c Antibody performance?

The performance of SPBPB2B2.19c Antibody is likely to vary significantly across different experimental conditions due to changes in epitope accessibility. This consideration is particularly important given that it's a polyclonal antibody targeting potentially multiple epitopes. Researchers should systematically evaluate:

• Native versus denatured conditions: Compare antibody binding in non-denaturing conditions (native PAGE, ELISA) versus denaturing conditions (SDS-PAGE, Western blot) to identify conformation-dependent epitopes.

• Fixation effects: If adapting for immunohistochemistry or immunofluorescence, test multiple fixation methods:

  • Paraformaldehyde (2-4%) for crosslinking fixation

  • Methanol for precipitative fixation

  • Acetone for preservation of certain antigens

• Buffer composition effects: Test binding efficiency across different pH ranges (5.5-8.5) and salt concentrations (150-500 mM NaCl) to identify optimal interaction conditions.

This systematic approach parallels methods used by researchers who discovered broadly neutralizing antibodies against SARS-CoV-2, where epitope accessibility under different conditions significantly impacted antibody performance .

What validation strategies should be implemented before using SPBPB2B2.19c Antibody in critical experiments?

Before employing the SPBPB2B2.19c Antibody in pivotal experiments, researchers should implement a comprehensive validation strategy:

• Specificity testing:

  • Western blot analysis comparing wild-type cells to knockout strains lacking SPBPB2B2.19c and/or SPBC1348.02

  • Peptide competition assays using the provided recombinant immunogen (200 μg)

  • Immunoprecipitation followed by mass spectrometry to identify all bound proteins

• Sensitivity determination:

  • Serial dilutions of recombinant target protein to establish detection limits

  • Comparison of signal intensity across various expression systems

• Reproducibility assessment:

  • Inter-lot comparison if multiple antibody lots are available

  • Cross-laboratory validation if collaborations permit

• Cross-reactivity profiling:

  • Testing against related S. pombe proteins with sequence similarity

  • Evaluation in other yeast species to determine species specificity

This rigorous validation approach mirrors the methodology used to verify antibody specificity in studies of preexisting cross-reactive antibodies to SARS-CoV-2, where distinguishing specific from non-specific binding was critical .

How can researchers quantitatively assess and compare SPBPB2B2.19c Antibody binding kinetics across experimental conditions?

To quantitatively assess binding kinetics of the SPBPB2B2.19c Antibody under different experimental conditions, researchers should implement the following methodological approaches:

• Surface Plasmon Resonance (SPR) analysis:

  • Immobilize purified target protein on a sensor chip

  • Inject antibody at different concentrations

  • Determine association (ka) and dissociation (kd) rate constants

  • Calculate equilibrium dissociation constant (KD = kd/ka)

• Bio-Layer Interferometry (BLI):

  • Alternative to SPR for real-time, label-free analysis

  • Compare binding rates under different buffer conditions

• Microscale Thermophoresis (MST):

  • Measure binding in solution without immobilization

  • Particularly useful when protein immobilization affects conformation

• Comparative data analysis:

  Experimental Condition	Association Rate (ka)	Dissociation Rate (kd)	Affinity (KD)
  pH 6.0	To be determined	To be determined	To be determined
  pH 7.4	To be determined	To be determined	To be determined
  150 mM NaCl	To be determined	To be determined	To be determined
  500 mM NaCl	To be determined	To be determined	To be determined

Similar quantitative approaches were utilized in characterizing monoclonal antibodies against coronavirus spike proteins, where researchers employed MST to determine binding affinities in the micromolar range (0.98-3.53 μM) .

What considerations should inform the development of multiplexed assays incorporating SPBPB2B2.19c Antibody?

When developing multiplexed assays that incorporate SPBPB2B2.19c Antibody alongside other detection reagents, researchers should consider several methodological factors:

• Antibody labeling strategies:

  • Direct fluorophore conjugation (e.g., Alexa Fluor dyes, quantum dots)

  • Biotin-streptavidin systems for signal amplification

  • Enzyme conjugates (HRP, AP) with spectrally distinct substrates

• Cross-reactivity mitigation:

  • Conduct pairwise testing of all antibodies in the multiplex panel

  • Implement sequential rather than simultaneous incubations if cross-reactivity occurs

  • Use monovalent Fab fragments instead of full IgG to reduce non-specific binding

• Signal normalization approach:

  • Include internal reference standards

  • Implement ratiometric analysis for quantitative comparisons

  • Utilize multi-parameter compensation matrices for fluorescence-based detection

• Data analysis algorithms:

  • Machine learning approaches for pattern recognition

  • Principal component analysis for distinguishing specific signals from background

This approach draws inspiration from bispecific antibody development strategies where researchers had to carefully address potential cross-reactivity and optimize signal detection in complex targeting systems .

How should researchers interpret unexpected molecular weight variations when detecting SPBPB2B2.19c target proteins?

When SPBPB2B2.19c Antibody detects proteins with unexpected molecular weights in Western blotting applications, researchers should systematically evaluate several potential explanations:

• Post-translational modifications (PTMs):

  • Phosphorylation typically adds ~80 Da per phosphate group

  • Glycosylation can add variable mass (1-100 kDa)

  • Ubiquitination adds ~8.5 kDa per ubiquitin moiety

• Alternative splicing:

  • Compare observed masses with predicted splice variants

  • Perform RT-PCR to verify expression of specific transcripts

• Proteolytic processing:

  • Test multiple extraction methods with different protease inhibitor cocktails

  • Compare fresh versus frozen samples to assess degradation effects

• Experimental artifacts:

  • Evaluate protein aggregation (higher MW) or incomplete denaturation

  • Test different reducing conditions (varying DTT/β-mercaptoethanol concentrations)

To systematically document these variations, researchers should create a comprehensive mapping table:

This analytical approach parallels methods used by researchers investigating antibody binding to coronavirus spike proteins, where unexpected binding patterns required systematic evaluation of protein modifications and processing events .

What strategies can address weak or inconsistent signals when using SPBPB2B2.19c Antibody?

When researchers encounter weak or inconsistent signals with SPBPB2B2.19c Antibody, the following methodological troubleshooting approach should be implemented:

• Sample preparation optimization:

  • Test multiple lysis buffers with varying detergent compositions

  • Implement subcellular fractionation to concentrate target proteins

  • Evaluate protein extraction efficiency via Coomassie staining

• Signal enhancement techniques:

  • Implement tyramide signal amplification for immunodetection

  • Use high-sensitivity chemiluminescent substrates (e.g., femto-level ECL)

  • Consider biotin-streptavidin amplification systems

• Protocol parameter optimization:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Test multiple blocking agents (BSA, milk, commercial blockers)

  • Optimize secondary antibody concentration and incubation conditions

• Antibody handling and storage:

  • Aliquot antibody to minimize freeze-thaw cycles

  • Add stabilizing proteins (BSA, 0.1-1%) to diluted antibody

  • Store at optimal temperature (typically -20°C or -80°C)

Researchers should document optimization results in a structured format:

This systematic optimization approach is similar to methods employed in developing highly sensitive detection systems for bispecific antibodies targeting low-abundance proteins .

How might SPBPB2B2.19c Antibody be adapted for super-resolution microscopy studies of S. pombe proteins?

Although the SPBPB2B2.19c Antibody is primarily validated for ELISA and Western blotting , adapting it for super-resolution microscopy requires specialized methodological considerations:

• Antibody fragmentation and labeling:

  • Generate Fab or F(ab')2 fragments to reduce linkage error

  • Site-specific labeling with small organic fluorophores (e.g., Alexa Fluor 647, Cy5.5)

  • Optimize dye-to-protein ratio (typically 1-2 fluorophores per fragment)

• Sample preparation optimization:

  • Test multiple fixation and permeabilization protocols

  • Implement epitope retrieval techniques if needed

  • Use specialized mounting media to induce fluorophore blinking

• Imaging parameters:

  • For STORM/PALM: Optimize photoswitching buffer composition

  • For STED: Select appropriate depletion laser parameters

  • For SIM: Establish optimal grating frequencies

• Quantitative validation:

  • Compare with conventional microscopy techniques

  • Implement fiducial markers for drift correction

  • Conduct resolution measurements using Fourier Ring Correlation

This approach draws on principles similar to those used in developing imaging techniques for tracking antibody-antigen interactions in complex cellular environments, as seen in studies of viral entry mechanisms .

What considerations should guide the development of a quantitative ELISA using SPBPB2B2.19c Antibody?

To develop a robust quantitative ELISA using SPBPB2B2.19c Antibody, researchers should implement the following methodological approach:

• Assay format selection:

  • Direct coating: Immobilize sample proteins directly

  • Sandwich: Use a capture antibody against a different epitope

  • Competition: Use the provided recombinant immunogen protein/peptide

• Standard curve development:

  • Purify target protein or use the provided recombinant immunogen

  • Prepare 2-fold serial dilutions (typically 8-12 points)

  • Include both high and low concentration controls

• Assay validation parameters:

  Parameter	Acceptance Criteria	Methodology
  Linearity	R² > 0.98	Linear regression analysis
  Sensitivity	Determine LLOD/LLOQ	Signal-to-noise ratio analysis
  Precision	CV < 15%	Intra/inter-assay variability testing
  Specificity	<10% cross-reactivity	Testing related proteins
  Recovery	80-120%	Spike-in experiments

• Data analysis approach:

  • 4 or 5-parameter logistic curve fitting

  • Parallel line analysis for comparing samples

  • Implement quality control rules (e.g., Westgard rules)

This quantitative approach is comparable to methods used in developing sensitive ELISA systems for detecting antibody responses in COVID-19 research, where distinguishing specific binding from background was critical .

What future research directions might expand the applications of SPBPB2B2.19c Antibody?

The current applications of SPBPB2B2.19c Antibody in ELISA and Western blotting represent only initial implementations that could be expanded in several promising research directions:

• Structural biology applications: Adapting the antibody for co-crystallization studies to determine the three-dimensional structure of target proteins or implementing negative staining electron microscopy for visualizing protein complexes.

• Functional studies: Developing neutralization assays to evaluate whether the antibody can inhibit specific protein functions, similar to approaches used with therapeutic antibodies targeting viral proteins .

• Single-cell analysis: Optimizing the antibody for mass cytometry or single-cell protein analysis to evaluate expression heterogeneity within S. pombe populations.

• Engineered derivatives: Exploring antibody engineering approaches similar to those used for bispecific antibodies to create dual-targeting reagents that could simultaneously detect multiple S. pombe proteins.

• Therapeutic applications: If the target proteins have homologs in pathogenic fungi, investigating potential therapeutic applications through humanization and affinity maturation techniques.